Bristol-Myers Squibb
BMY
2,359 hedge funds and large institutions have $104B invested in Bristol-Myers Squibb in 2020 Q4 according to their latest regulatory filings, with 286 funds opening new positions, 949 increasing their positions, 869 reducing their positions, and 108 closing their positions.
165% more first-time investments, than exits
New positions opened: 286 | Existing positions closed: 108
7% more funds holding
Funds holding: 2,214 → 2,359 (+145)
10% more call options, than puts
Call options by funds: $1.51B | Put options by funds: $1.38B
9% more repeat investments, than reductions
Existing positions increased: 949 | Existing positions reduced: 869
4% more capital invested
Capital invested by funds: $100B → $104B (+$3.72B)
0.37% less ownership
Funds ownership: 74.06% → 73.69% (-0.37%)
16% less funds holding in top 10
Funds holding in top 10: 93 → 78 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$618M |
| 2 |
JP Morgan Chase
New York
|
+$368M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$311M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$239M |
| 5 |
Morgan Stanley
New York
|
+$237M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$744M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$507M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$430M |
| 4 |
Two Sigma Advisers
New York
|
-$242M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$215M |
BMY Hedge Fund Activity: Q4 2020 in Review
2,359 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2020, worth a combined $104B — up 3.7% from $100B a quarter earlier.
Buyers outnumbered sellers: 286 funds opened new BMY positions and 108 closed out — a net gain of 178 holders — while 949 added to existing stakes and 869 trimmed.
The largest buyer was BlackRock, adding an estimated $618M. The largest seller was Renaissance Technologies, cutting an estimated $744M.
- 2,359 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2020, up from 2,214 in Q3 2020.
- Funds reported $104B of Bristol-Myers Squibb stock for Q4 2020, up 3.7% quarter-over-quarter.
- 286 funds opened new Bristol-Myers Squibb positions in Q4 2020 and 108 closed out, a net change of +178 holders.
- The largest Bristol-Myers Squibb buyer in Q4 2020 was BlackRock, an estimated $618M added.
- The largest Bristol-Myers Squibb seller in Q4 2020 was Renaissance Technologies, an estimated $744M sold.
Based on aggregated 13F filings for Q4 2020.